EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Smolen, JS; Landewe, RBM; Bijlsma, JWJ; Burmester, GR; Dougados, M; Kerschbaumer, A; McInnes, IB; Sepriano, A; van Vollenhoven, RF; de Wit, M; Aletaha, D; Aringer, M; Askling, J; Balsa, A; Boers, M; den Broeder, AA; Buch, MH; Buttgereit, F; Caporali, R; Cardiel, MH; De Cock, D; Codreanu, C; Cutolo, M; Edwards, CJ; van Eijk-Hustings, Y; Emery, P; Finckh, A; Gossec, L; Gottenberg, JE; Hetland, ML; Huizinga, TWJ; Koloumas, M; Li, ZG; Mariette, X; Muller-Ladner, U; Mysler, EF; da Silva, JAP; Poor, G; Pope, JE; Rubbert-Roth, A; Ruyssen-Witrand, A; Saag, KG; Strangfeld, A; Takeuchi, T; Voshaar, M; Westhovens, R; van der Heijde, D
Smolen, JS (corresponding author), Med Univ Vienna, Div Rheumatol, Dept Med 3, A-1090 Vienna, Austria.
ANNALS OF THE RHEUMATIC DISEASES, 2020; 79 (6): 685
